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The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm
(BA), which cross-check FibroTest with the aspartate aminotransferase-to-platelet
ratio index (APRI) or FibroScan, are very accurate but provide only a binary
diagnosis of significant fibrosis (SAFE or BA for Metavir F ≥ 2) or cirrhosis (SAFE or
BA for F4). Therefore, in clinical practice, physicians have to apply the algorithm for
F ≥ 2, and then, when needed, the algorithm for F4 (“successive algorithms”). We
aimed to evaluate successive SAFE, successive BA, and a new, noninvasive, detailed
classification of fibrosis. The study included 1785 patients with chronic hepatitis C,
liver biopsy, blood fibrosis tests, and FibroScan (the latter in 729 patients). The most
accurate synchronous combination of FibroScan with a blood test (FibroMeter)
provided a new detailed (six classes) classification (FM+FS). Successive SAFE had a
significantly (P < 10−3) lower diagnostic accuracy (87.3%) than individual SAFE for
F ≥ 2 (94.6%) or SAFE for F4 (89.5%), and required significantly more biopsies
(70.8% versus 64.0% or 6.4%, respectively, P < 10−3). Similarly, successive BA had
significantly (P ≤ 10−3) lower diagnostic accuracy (84.7%) than individual BA for F
≥ 2 (88.3%) or BA for F4 (94.2%), and required significantly more biopsies (49.8%
versus 34.6% or 24.6%, respectively, P < 10−3). The diagnostic accuracy of the
FM+FS classification (86.7%) was not significantly different from those of successive
SAFE or BA. However, this new classification required no biopsy. Conclusion: SAFE
and BA for significant fibrosis or cirrhosis are very accurate. However, their
successive use induces a significant decrease in diagnostic accuracy and a significant
increase in required liver biopsy. A new fibrosis classification that synchronously
combines two fibrosis tests was as accurate as successive SAFE or BA, while
providing an entirely noninvasive (0% liver biopsy) and more precise (six versus two
or three fibrosis classes) fibrosis diagnosis.
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